Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Belgium / NCT07172243
Recruiting Observational

BE.Amycon Biobank & Data Registry UZ Leuven

NCT07172243 · tracked via the Priya Life Science Belgium tracker
Sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Observational
Started
2025-09-24
Last updated
2026-09-25

Condition(s) studied

AmyloidosisAL AmyloidosisAmyloidosis Cardiac

Study summary

The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database "BE.Amycon data registry".

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Provide consent and sign informed consent form * Age 18 years or older * Diagnosis of amyloidosis (suspected or confirmed, any subtypes) * For the prospective sample collection only: newly diagnosed (any subtype) or at relapse (AL amyloidosis) Exclusion Criteria: * Not willing to sign informed consent * Not able to sign informed consent

Primary outcome measure(s)

  • Establishment of a data registry: participant baseline demographics — Baseline
    Demographic characteristics of amyloidosis participants will be assessed at baseline.
  • Establishment of a data registry: description of the disease characteristics of patients with amyloidosis at diagnosis — Baseline
    Disease characteristics of amyloidosis (disease presentation and symptoms, type of organ involvment, results of diagnostic tests (lab values, imaging, biopsy)) will be collected at moment of diagnosis.
  • Establishment of a data registry: treatment in participants with amyloidosis — From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years
    Description of treatment (type of treatment per line of treatment) of participants with amyloidosis within routine clinical care.
  • Establishment of a biobank with biological samples (blood, urine, tissue) from patients with amyloidosis — From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 2 years
    Biological samples (blood, urine, tissue) will be collected from patients with amyloidosis.

Trial sites (2)

FacilityCityRegionStatus
UZ Leuven Gasthuisberg - hematology Leuven Belgium Recruiting
UZ Leuven Gasthuisberg - cardiology Leuven Belgium Recruiting

More Universitaire Ziekenhuizen KU Leuven trials in Belgium

A Study to Investigate the Effect of a Meal At 6pm the Day Before the Colonoscopy on the Bowel Cleansing with Plenvu Active, not recruiting
Follow-up and Outcome of Operative Treatment With Decompressive Release Of The Peroneal Nerve Recruiting
GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis Recruiting
Cochlear Implantation for Young Single-sided Deaf Children Active, not recruiting
Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt Recruiting

Other trials for the same condition

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) Active, not recruiting
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause. Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07172243 on ClinicalTrials.gov ↗ ← All trials in Belgium